The Clinical Performance of the Biofinity Contact Lens (Comfilcon A) With Two Lens Care Systems

CooperVision, Inc.51 enrolled

Overview

This will be a controlled and randomized, single-masked, crossover study in which 48 subjects will use the Biofinity Contact Lens (comfilcon A) with each of the two lens care products ('solutions'), (Synergi and Biotrue Multi-purpose Solution) for one month each. Follow-up visits for each solution will take place at one week, two weeks and four weeks: with a one-week 'wash-out' period between the solutions. Key outcome measures for this study include biomicroscopic and subjective responses to the lens/solution combinations.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

SINGLE

Enrollment

Conditions

Myopia

Interventions

comfilcon ADEVICE

soft contact lens

SynergiDEVICE

Multipurpose solution

BiotrueDEVICE

Multipurpose solution

stenfilcon A

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: 1. They are of legal age and capacity to volunteer. 2. They understand their rights as a research subject and are willing and able to sign a Statement of Informed Consent. 3. They are willing and able to follow the protocol. 4. They agree not to participate in other clinical research for the duration of this study. 5. They have a contact lens spherical prescription between - 0.50 to - 6.00 (inclusive) 6. They have a spectacle cylindrical correction of -1.00D (Diopters) or less in each eye. 7. At dispensing, they can attain at least 0.10 logMAR distance high contrast visual acuity in each eye with the study lenses within the available power range. 8. They currently use silicone hydrogel soft contact lenses. 9. They are willing to comply with the wear schedule (at least 5 days per week, ≥8 hours/day). Exclusion Criteria: 1. They have an ocular disorder which would normally contra-indicate contact lens wear. 2. They have a systemic disorder which would normally contra-indicate contact lens wear. 3. They are using any topical medication such as eye drops or ointment. 4. They have had cataract surgery. 5. They have had corneal refractive surgery. 6. They have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus. 7. They are pregnant or lactating. 8. They have any ocular abnormality which would, in the opinion of the investigator, normally contraindicate contact lens wear. 9. They have any infectious disease which would, in the opinion of the investigator, contraindicate contact lens wear or pose a risk to study personnel; or they have any immunosuppressive disease (e.g. HIV), or a history of anaphylaxis or severe allergic reaction. 10. They have taken part in any other contact lens or care solution clinical trial or research, within two weeks prior to starting this study.

Locations (1)

Eurolens Research

Manchester, United Kingdom

Outcomes

Primary Outcomes

Conjunctival Hyperaemia

Conjunctival hyperaemia of Synergi / comfilcon A combination and Biotrue / comfilcon A combination assessed at baseline, 1 week, 2 week, and 4 week follow-up visits. Grades 0-4, 0=normal, 4=severe.

Time frame: Baseline, 1 week, 2 weeks, 4 weeks

Limbal Hyperaemia

Limbal hyperaemia of Synergi / comfilcon A combination and Biotrue / comfilcon A combination assessed at baseline, 1 week, 2 week, and 4 week follow-up visits. Grades 0-4, 0=normal, 4=severe.

Time frame: Baseline, 1 week, 2 weeks, 4 weeks

Corneal Staining

Corneal staining of Synergi / comfilcon A combination and Biotrue / comfilcon A combination assessed at baseline, 1 week, 2 week, and 4 week follow-up visits. Grades 0-4, 0=none, 4=patch.

Time frame: Baseline, 1 week, 2 weeks, 4 weeks

Papillary Conjunctivitis

Papillary conjunctivitis of Synergi / comfilcon A combination and Biotrue / comfilcon A combination assessed at baseline, 1 week, 2 week, and 4 week follow-up visits. Grades 0-4, 0=normal, 4=severe.

Time frame: Baseline, 1 week, 2 weeks, 4 weeks

Comfort

Subjective comfort for Synergi / comfilcon A combination and Biotrue / comfilcon A combination is assessed at 1 week visit. Scale 0-100, 0=causes pain, cannot be tolerated, 100=excellent, cannot be felt.

Time frame: 1 week

Comfort

Subjective comfort for Synergi / comfilcon A combination and Biotrue / comfilcon A combination is assessed at 2 week visit. Scale 0-100, 0=causes pain, cannot be tolerated, 100=excellent, cannot be felt.

Time frame: 2 weeks

Comfort

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.